Une mutation unique de la protéine kinase JAK2 dans la polyglobulie de Vaquez et les syndromes myéloprolifératifs non-LMC
Med Sci (Paris), 21 6-7 (2005) 669-670
Published online: 2005-06-15
Articles citing this article
The Citing articles tool gives a list of articles citing the current article.
The citing articles come from EDP Sciences database, as well as other publishers participating in CrossRef Cited-by Linking Program. You can set up your personal account to receive an email alert each time this article is cited by a new article (see the menu on the right-hand side of the abstract page).
Cited article:
This article has been cited by the following article(s):
DUSP6, une cible potentielle pour empêcher la progression leucémique des néoplasmes myéloprolifératifs
Quentin Provôt, Nathan Fiévet, Yasmine Liza Mechouek, Iléana Antony-Debré and Brahim Arkounmédecine/sciences 40 (11) 876 (2024)
https://doi.org/10.1051/medsci/2024156
569 (2024)
https://doi.org/10.1016/B978-0-12-822824-1.00027-4
Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry
Vikas Bhuria, Tobias Franz, Conny Baldauf, Martin Böttcher, Nicolas Chatain, Steffen Koschmieder, Tim H. Brümmendorf, Dimitrios Mougiakakos, Burkhart Schraven, Sascha Kahlfuß and Thomas FischerCell Communication and Signaling 22 (1) (2024)
https://doi.org/10.1186/s12964-024-01530-z
Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved
Vikas Bhuria, Conny K. Baldauf, Burkhart Schraven and Thomas FischerInternational Journal of Molecular Sciences 23 (6) 3206 (2022)
https://doi.org/10.3390/ijms23063206
JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
Michael Stephan Bader and Sara Christina MeyerPharmaceuticals 15 (2) 160 (2022)
https://doi.org/10.3390/ph15020160
The Mutational Landscape of Myeloid Leukaemia in Down Syndrome
Carini Picardi Morais de Castro, Maria Cadefau and Sergi CuarteroCancers 13 (16) 4144 (2021)
https://doi.org/10.3390/cancers13164144
Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A
Salma MerchantInternational Review of Cell and Molecular Biology, Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A 365 117 (2021)
https://doi.org/10.1016/bs.ircmb.2021.09.002
Role of inflammation in the biology of myeloproliferative neoplasms
Steffen Koschmieder and Nicolas ChatainBlood Reviews 42 100711 (2020)
https://doi.org/10.1016/j.blre.2020.100711
Zebrafish for thrombocytopoiesis- and hemostasis-related researches and disorders
Panpan Meng, Liangliang Wu, Qing Lin and Yiyue ZhangBlood Science 2 (2) 44 (2020)
https://doi.org/10.1097/BS9.0000000000000043
In Vitro Vascular-Protective Effects of a Tilapia By-Product Oligopeptide on Angiotensin II-Induced Hypertensive Endothelial Injury in HUVEC by Nrf2/NF-κB Pathways
Jiali Chen, Fang Gong, Mei-Fang Chen, et al.Marine Drugs 17 (7) 431 (2019)
https://doi.org/10.3390/md17070431
Antimalarial drug artemisinin depletes erythrocytes by activating apoptotic pathways in zebrafish
Ran Yang, Shouyu Yan, Xiaojun Zhu, et al.Experimental Hematology 43 (4) 331 (2015)
https://doi.org/10.1016/j.exphem.2014.11.012
Effects of Jak2 Type 1 Inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 Mutation-Positive and Bcr-Abl-Positive Cell Lines
Frauke Ringel, Jaspal Kaeda, Michaela Schwarz, et al.Acta Haematologica 132 (1) 75 (2014)
https://doi.org/10.1159/000356784
HSP70 un régulateur de l’érythropoïèse qui détermine le destin des érythroblastes entre mort et différenciation
O. Hermine, J.-B. Arlet, J.-A. Ribeil, et al.Transfusion Clinique et Biologique 20 (2) 144 (2013)
https://doi.org/10.1016/j.tracli.2013.03.005
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm
Santiago Barrio, Miguel Gallardo, Alicia Arenas, Rosa Ayala, Inmaculada Rapado, Daniel Rueda, Ana Jiménez‐Ubieto, Enriqueta Albizua, Carmen Burgaleta, Florinda Gilsanz and Joaquin Martinez‐LopezBritish Journal of Haematology 161 (5) 667 (2013)
https://doi.org/10.1111/bjh.12308
647 (2012)
https://doi.org/10.1002/9781118464557.ch47
L’ETO se resserre sur les leucémies aiguës mégacaryoblastiques
Clarisse Thiollier, Françoise Pflumio, Paola Ballerini, et al.médecine/sciences 28 (11) 1013 (2012)
https://doi.org/10.1051/medsci/20122811025
Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation
S Barrio, M Gallardo, E Albizua, A Jimenez, I Rapado, R Ayala, F Gilsanz, J I Martin-Subero and J Martinez-LopezJournal of Clinical Pathology 64 (11) 1010 (2011)
https://doi.org/10.1136/jclinpath-2011-200175
Du symptôme à la prescription en médecine générale
N. CasadevallDu symptôme à la prescription en médecine générale 720 (2009)
https://doi.org/10.1016/B978-2-294-01781-0.50136-9
Hsp70, l’ange gardien de GATA-1 lors de la différenciation des globules rouges
Julie Vandekerckhove, Jean-Antoine Ribeil, Yaël Zermati, et al.médecine/sciences 24 (1) 37 (2008)
https://doi.org/10.1051/medsci/200824137
JAK2 and MPL Mutations in Myeloproliferative Neoplasms
Priya Koppikar and Ross L. LevineActa Haematologica 119 (4) 218 (2008)
https://doi.org/10.1159/000140634
Syndrome de Budd-Chiari
Aurélie PlessierGastroentérologie Clinique et Biologique 30 (10) 1162 (2006)
https://doi.org/10.1016/S0399-8320(06)73495-9
Syndrome de Budd-Chiari
A. Plessier and D. VallaEMC - Hépatologie 1 (4) 1 (2006)
https://doi.org/10.1016/S1155-1976(06)41408-X